These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 27653164

  • 1. Fixed-dose combination of zofenopril plus hydrochlorothiazide vs. irbesartan plus hydrochlorothiazide in hypertensive patients with established metabolic syndrome uncontrolled by previous monotherapy. The ZAMES study (Zofenopril in Advanced MEtabolic Syndrome).
    Napoli C, Omboni S, Borghi C, ZAMES (Zofenopril in Advanced MEtabolic Syndrome) Study Group.
    J Hypertens; 2016 Nov; 34(11):2287-97. PubMed ID: 27653164
    [Abstract] [Full Text] [Related]

  • 2. Zofenopril plus hydrochlorothiazide and irbesartan plus hydrochlorothiazide in previously treated and uncontrolled diabetic and non-diabetic essential hypertensive patients.
    Agabiti-Rosei E, Manolis A, Zava D, Omboni S, ZODIAC Study Group.
    Adv Ther; 2014 Feb; 31(2):217-33. PubMed ID: 24415271
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of Zofenopril vs. Irbesartan in Combination with a Thiazide Diuretic in Hypertensive Patients with Multiple Risk Factors not Controlled by a Previous Monotherapy: A Review of the Double-Blind, Randomized "Z" Studies.
    Omboni S, Malacco E, Napoli C, Modesti PA, Manolis A, Parati G, Agabiti-Rosei E, Borghi C.
    Adv Ther; 2017 Apr; 34(4):784-798. PubMed ID: 28260186
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. BP goal achievement in patients with uncontrolled hypertension : results of the treat-to-target post-marketing survey with irbesartan.
    Schrader J, Bramlage P, Lüders S, Thoenes M, Schirmer A, Paar DW.
    Clin Drug Investig; 2007 Apr; 27(11):783-96. PubMed ID: 17914897
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Comparison of the antihypertensive activity of fosinopril and irbesartan].
    Angulo E, Robles NR, Grois J, Barquero A, Pérez Miranda M.
    An Med Interna; 2002 Nov; 19(11):571-5. PubMed ID: 12522893
    [Abstract] [Full Text] [Related]

  • 9. Antihypertensive efficacy of zofenopril plus hydrochlorothiazide fixed combination for treatment in metabolic syndrome.
    Malacco E, Omboni S.
    Adv Ther; 2007 Nov; 24(5):1006-15. PubMed ID: 18029326
    [Abstract] [Full Text] [Related]

  • 10. Antihypertensive effect of zofenopril plus hydrochlorothiazide versus zofenopril monotherapy in patients with essential hypertension according to their cardiovascular risk level: A post hoc analysis.
    Malacco E, Omboni S, Study Group.
    Curr Ther Res Clin Exp; 2008 Jun; 69(3):232-42. PubMed ID: 24692801
    [Abstract] [Full Text] [Related]

  • 11. Once-daily fixed-combination irbesartan 300 mg/ hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension.
    Coca A, Calvo C, Sobrino J, Gómez E, López-Paz JE, Sierra C, Bragulat E, de la Sierra A.
    Clin Ther; 2003 Nov; 25(11):2849-64. PubMed ID: 14693309
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorización Ambulatoria Presión Arterial APROVEL).
    Coca A, Calvo C, García-Puig J, Gil-Extremera B, Aguilera MT, de la Sierra A, Martín-Hidalgo A, Marín R, MAPAVEL Investigators (Monitorizacíon Ambulatoria Presión Arterial APROVEL).
    Clin Ther; 2002 Jan; 24(1):126-38. PubMed ID: 11833827
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy.
    Cushman WC, Neutel JM, Saunders E, Bakris GL, Ferdinand KC, Ofili EO, Sowers JR, Madder R, Weber MA.
    Am J Geriatr Cardiol; 2008 Jan; 17(1):27-36. PubMed ID: 18174757
    [Abstract] [Full Text] [Related]

  • 17. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations.
    Bobrie G, Delonca J, Moulin C, Giacomino A, Postel-Vinay N, Asmar R, COmparative Study of Efficacy of Irbesartan/HCTZ with Valsartan/HCTZ Using Home Blood Pressure Monitoring in the TreAtment of Mild-to-Moderate Hypertension (COSIMA) Investigators.
    Am J Hypertens; 2005 Nov; 18(11):1482-8. PubMed ID: 16280286
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM, Malacco E, Khder Y, Kandra A, Bönner G, Heintz D.
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [Abstract] [Full Text] [Related]

  • 19. A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertension.
    Lacourcière Y.
    Clin Ther; 2000 Oct; 22(10):1213-24. PubMed ID: 11110232
    [Abstract] [Full Text] [Related]

  • 20. Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes.
    Sowers JR, Neutel JM, Saunders E, Bakris GL, Cushman WC, Ferdinand KC, Ofili EO, Weber MA, INCLUSIVE Investigators.
    J Clin Hypertens (Greenwich); 2006 Jul; 8(7):470-80. PubMed ID: 16849900
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.